Drugs / Prostap® 3 DCS
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT01673984 Comparator | Aug 2012 → Feb 2014 | prostate cancer | Ipsen | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Prostap 3 DCS | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01673984 ↗ |
| Route | Subcutaneous | “11.25mg, depot injected subcutaneously” NCT01673984 ↗ |